Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Comparative Effectiveness of Operative Versus Nonoperative Treatment for Rotator Cuff Tears: A Propensity Score Analysis From the ROW Cohort.

Jain NB, Ayers GD, Fan R, Kuhn JE, Warner JJP, Baumgarten KM, Matzkin E, Higgins LD.

Am J Sports Med. 2019 Sep 13:363546519873840. doi: 10.1177/0363546519873840. [Epub ahead of print]

PMID:
31518155
2.

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.

Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, Johnson DB, Al-Rohil RN, Halilovic E, Kauffmann RM, Kelley M, Ayers GD, Richmond A.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaav7171. doi: 10.1126/scitranslmed.aav7171.

PMID:
31413145
3.

Operative vs Nonoperative Treatment for Atraumatic Rotator Cuff Tears: A Trial Protocol for the Arthroscopic Rotator Cuff Pragmatic Randomized Clinical Trial.

Jain NB, Ayers GD, Koudelková H, Archer KR, Dickinson R, Richardson B, Derryberry M, Kuhn JE; ARC Trial Group.

JAMA Netw Open. 2019 Aug 2;2(8):e199050. doi: 10.1001/jamanetworkopen.2019.9050.

4.

Which Is the Best Outcome Measure for Rotator Cuff Tears?

Dabija DI, Pennings JS, Archer KR, Ayers GD, Higgins LD, Kuhn JE, Baumgarten KM, Matzkin E, Jain NB.

Clin Orthop Relat Res. 2019 Aug;477(8):1869-1878. doi: 10.1097/CORR.0000000000000800.

PMID:
31335605
5.

Physical therapy versus natural history in outcomes of rotator cuff tears: the Rotator Cuff Outcomes Workgroup (ROW) cohort study.

Dickinson RN, Ayers GD, Archer KR, Fan R, Page C, Higgins LD, Kuhn JE, Baumgarten KM, Matzkin E, Jain NB.

J Shoulder Elbow Surg. 2019 May;28(5):833-838. doi: 10.1016/j.jse.2018.10.001. Epub 2018 Dec 13.

PMID:
30553798
6.

PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.

Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, Chioma OS, Lee G, Hassell NE, Shaginurova GI, Wang Y, Johnson JE, Kerrigan A, Mason WR, Baughman RP, Ayers GD, Bernard GR, Culver DA, Montgomery CG, Maher TM, Molyneaux PL, Noth I, Mutsaers SE, Prele CM, Peebles RS Jr, Newcomb DC, Kaminski N, Blackwell TS, Van Kaer L, Drake WP.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaar8356. doi: 10.1126/scitranslmed.aar8356.

7.

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, Ayers GD, Olejniczak ET, Fesik SW, Savona MR.

Cancer Discov. 2018 Dec;8(12):1566-1581. doi: 10.1158/2159-8290.CD-18-0140. Epub 2018 Sep 5.

8.

Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.

Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, Joyce S, Richmond A.

Cancer Immunol Res. 2018 Oct;6(10):1186-1198. doi: 10.1158/2326-6066.CIR-18-0045. Epub 2018 Aug 14.

PMID:
30108045
9.

Predictors of Pain and Functional Outcomes After the Nonoperative Treatment of Rotator Cuff Tears.

Jain NB, Ayers GD, Fan R, Kuhn JE, Baumgarten K, Matzkin E, Higgins LD.

Orthop J Sports Med. 2018 Aug 3;6(8):2325967118788531. doi: 10.1177/2325967118788531. eCollection 2018 Aug.

10.

Does My Patient With Shoulder Pain Have a Rotator Cuff Tear?: A Predictive Model From the ROW Cohort.

Jain NB, Fan R, Higgins LD, Kuhn JE, Ayers GD.

Orthop J Sports Med. 2018 Jul 16;6(7):2325967118784897. doi: 10.1177/2325967118784897. eCollection 2018 Jul.

11.

Predictors of pain and functional outcomes after operative treatment for rotator cuff tears.

Jain NB, Ayers GD, Fan R, Kuhn JE, Baumgarten KM, Matzkin E, Higgins LD.

J Shoulder Elbow Surg. 2018 Aug;27(8):1393-1400. doi: 10.1016/j.jse.2018.04.016.

12.

Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells.

Zhang Q, Jeppesen DK, Higginbotham JN, Demory Beckler M, Poulin EJ, Walsh AJ, Skala MC, McKinley ET, Manning HC, Hight MR, Schulte ML, Watt KR, Ayers GD, Wolf MM, Andrejeva G, Rathmell JC, Franklin JL, Coffey RJ.

Cell Mol Gastroenterol Hepatol. 2018 Jan 31;5(4):627-629.e6. doi: 10.1016/j.jcmgh.2018.01.013. eCollection 2018. No abstract available.

13.

Maintaining oncologic integrity with minimally invasive resection of pediatric embryonal tumors.

Phelps HM, Ayers GD, Ndolo JM, Dietrich HL, Watson KD, Hilmes MA, Lovvorn HN 3rd.

Surgery. 2018 Aug;164(2):333-343. doi: 10.1016/j.surg.2018.03.020. Epub 2018 May 8.

14.

MDM2 Antagonists Counteract Drug-Induced DNA Damage.

Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A.

EBioMedicine. 2017 Oct;24:43-55. doi: 10.1016/j.ebiom.2017.09.016. Epub 2017 Sep 19.

15.

Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.

Li C, Singh B, Graves-Deal R, Ma H, Starchenko A, Fry WH, Lu Y, Wang Y, Bogatcheva G, Khan MP, Milne GL, Zhao S, Ayers GD, Li N, Hu H, Washington MK, Yeatman TJ, McDonald OG, Liu Q, Coffey RJ.

Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2852-E2861. doi: 10.1073/pnas.1618297114. Epub 2017 Mar 20.

16.

A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer.

Cardin DB, Thota R, Goff LW, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E.

Am J Clin Oncol. 2018 Aug;41(8):772-776. doi: 10.1097/COC.0000000000000377.

17.

Mutations underlying Episodic Ataxia type-1 antagonize Kv1.1 RNA editing.

Ferrick-Kiddie EA, Rosenthal JJ, Ayers GD, Emeson RB.

Sci Rep. 2017 Feb 20;7:41095. doi: 10.1038/srep41095.

18.

The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo.

Lavender N, Yang J, Chen SC, Sai J, Johnson CA, Owens P, Ayers GD, Richmond A.

BMC Cancer. 2017 Jan 31;17(1):88. doi: 10.1186/s12885-017-3074-2.

19.

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A.

Clin Cancer Res. 2017 Jul 1;23(13):3371-3384. doi: 10.1158/1078-0432.CCR-16-2142. Epub 2016 Dec 21. Erratum in: Clin Cancer Res. 2018 Aug 1;24(15):3782.

20.

Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo.

Schulte ML, Hight MR, Ayers GD, Liu Q, Shyr Y, Washington MK, Manning HC.

Mol Imaging Biol. 2017 Jun;19(3):421-428. doi: 10.1007/s11307-016-1008-z.

21.

Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience.

Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, Clark SW.

Mol Clin Oncol. 2016 Feb;4(2):154-158. Epub 2015 Dec 4.

22.

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A.

J Natl Cancer Inst. 2015 Dec 30;108(6):djv406. doi: 10.1093/jnci/djv406. Print 2016 Jun.

23.

On the Use of DSC-MRI for Measuring Vascular Permeability.

Skinner JT, Moots PL, Ayers GD, Quarles CC.

AJNR Am J Neuroradiol. 2016 Jan;37(1):80-7. doi: 10.3174/ajnr.A4478. Epub 2015 Oct 1.

24.

Traumatic spinal cord injury in the United States, 1993-2012.

Jain NB, Ayers GD, Peterson EN, Harris MB, Morse L, O'Connor KC, Garshick E.

JAMA. 2015 Jun 9;313(22):2236-43. doi: 10.1001/jama.2015.6250.

25.

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA.

Cancer Immunol Res. 2015 Mar;3(3):288-295. doi: 10.1158/2326-6066.CIR-14-0207.

26.

Effective Tobacco Cessation via Health Coaching: An Institutional Case Report.

Sforzo GA, Kaye M, Ayers GD, Talbert B, Hill M.

Glob Adv Health Med. 2014 Sep;3(5):37-44. doi: 10.7453/gahmj.2014.029.

27.

SIX2 Effects on Wilms Tumor Biology.

Pierce J, Murphy AJ, Panzer A, de Caestecker C, Ayers GD, Neblett D, Saito-Diaz K, de Caestecker M, Lovvorn HN 3rd.

Transl Oncol. 2014 Dec;7(6):800-11. doi: 10.1016/j.tranon.2014.09.005.

28.

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A.

Cancer Res. 2015 Jan 1;75(1):181-93. doi: 10.1158/0008-5472.CAN-14-2405. Epub 2014 Nov 14.

29.

Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response.

Yang J, Hawkins OE, Barham W, Gilchuk P, Boothby M, Ayers GD, Joyce S, Karin M, Yull FE, Richmond A.

Cancer Res. 2014 Dec 15;74(24):7274-84. doi: 10.1158/0008-5472.CAN-14-1091. Epub 2014 Oct 21.

30.

Reovirus-mediated induction of ADAR1 (p150) minimally alters RNA editing patterns in discrete brain regions.

Hood JL, Morabito MV, Martinez CR 3rd, Gilbert JA, Ferrick EA, Ayers GD, Chappell JD, Dermody TS, Emeson RB.

Mol Cell Neurosci. 2014 Jul;61:97-109. doi: 10.1016/j.mcn.2014.06.001. Epub 2014 Jun 4.

31.

The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.

Saville BR, Connor JT, Ayers GD, Alvarez J.

Clin Trials. 2014 Aug;11(4):485-493. Epub 2014 May 28.

32.

Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer.

Li C, Ma H, Wang Y, Cao Z, Graves-Deal R, Powell AE, Starchenko A, Ayers GD, Washington MK, Kamath V, Desai K, Gerdes MJ, Solnica-Krezel L, Coffey RJ.

J Clin Invest. 2014 May;124(5):2172-87. Epub 2014 Apr 1.

33.

The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.

Vear SI, Ayers GD, Van Driest SL, Sidonio RF, Stein CM, Ho RH.

Br J Haematol. 2014 Jun;165(6):832-5. doi: 10.1111/bjh.12817. Epub 2014 Mar 6.

34.

A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: a step towards practical implementation.

Fedorov A, Fluckiger J, Ayers GD, Li X, Gupta SN, Tempany C, Mulkern R, Yankeelov TE, Fennessy FM.

Magn Reson Imaging. 2014 May;32(4):321-9. doi: 10.1016/j.mri.2014.01.004. Epub 2014 Jan 21.

35.

CITED1 confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus.

Murphy AJ, Pierce J, de Caestecker C, Ayers GD, Zhao A, Krebs JR, Saito-Diaz VK, Lee E, Perantoni AO, de Caestecker MP, Lovvorn HN 3rd.

Oncotarget. 2014 Jan 30;5(2):386-402.

36.

Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors?

Gonzalez RS, Liu EH, Alvarez JR, Ayers GD, Washington MK, Shi C.

Mod Pathol. 2014 Sep;27(9):1288-95. doi: 10.1038/modpathol.2013.232. Epub 2014 Jan 24.

37.

Tumor deposits in rectal adenocarcinoma after neoadjuvant chemoradiation are associated with poor prognosis.

Gopal P, Lu P, Ayers GD, Herline AJ, Washington MK.

Mod Pathol. 2014 Sep;27(9):1281-7. doi: 10.1038/modpathol.2013.239. Epub 2014 Jan 17.

38.

Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer.

Whisenant JG, Ayers GD, Loveless ME, Barnes SL, Colvin DC, Yankeelov TE.

Magn Reson Imaging. 2014 Apr;32(3):245-9. doi: 10.1016/j.mri.2013.10.013. Epub 2013 Dec 14.

39.

CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways.

Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS, Richmond A.

Mol Biol Cell. 2014 Mar;25(5):566-82. doi: 10.1091/mbc.E13-07-0360. Epub 2014 Jan 8.

40.

Imaging analysis of hepatoblastoma resectability across neoadjuvant chemotherapy.

Murphy AJ, Ayers GD, Hilmes MA, Mukherjee K, Wilson KJ, Allen WM, Fernandez-Pineda I, Shinall MC Jr, Zhao Z, Furman WL, McCarville MB, Davidoff AM, Lovvorn HN 3rd.

J Pediatr Surg. 2013 Jun;48(6):1239-48. doi: 10.1016/j.jpedsurg.2013.03.019.

41.

DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings.

Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE.

Magn Reson Med. 2014 Apr;71(4):1592-602. doi: 10.1002/mrm.24782. Epub 2013 May 9.

42.

Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.

McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, Coffey RJ, Manning HC.

PLoS One. 2013;8(3):e58938. doi: 10.1371/journal.pone.0058938. Epub 2013 Mar 15.

43.

CITED1 expression in liver development and hepatoblastoma.

Murphy AJ, de Caestecker C, Pierce J, Boyle SC, Ayers GD, Zhao Z, Libes JM, Correa H, Walter T, Huppert SS, Perantoni AO, de Caestecker MP, Lovvorn HN 3rd.

Neoplasia. 2012 Dec;14(12):1153-63.

44.

Amide proton transfer imaging of the breast at 3 T: establishing reproducibility and possible feasibility assessing chemotherapy response.

Dula AN, Arlinghaus LR, Dortch RD, Dewey BE, Whisenant JG, Ayers GD, Yankeelov TE, Smith SA.

Magn Reson Med. 2013 Jul;70(1):216-24. doi: 10.1002/mrm.24450. Epub 2012 Aug 20.

45.

Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer.

Barnes SL, Whisenant JG, Loveless ME, Ayers GD, Yankeelov TE.

Magn Reson Med. 2013 Jun;69(6):1721-34. doi: 10.1002/mrm.24422. Epub 2012 Jul 27.

46.

INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma.

Yang J, Kantrow S, Sai J, Hawkins OE, Boothby M, Ayers GD, Young ED, Demicco EG, Lazar AJ, Lev D, Richmond A.

Cancer Res. 2012 Sep 15;72(18):4682-95. doi: 10.1158/0008-5472.CAN-12-0440. Epub 2012 Jul 26. Erratum in: Cancer Res. 2013 Aug 1;73(15):4962.

47.

Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.

Whisenant JG, Peterson TE, Fluckiger JU, Tantawy MN, Ayers GD, Yankeelov TE.

Mol Imaging Biol. 2013 Feb;15(1):87-96. doi: 10.1007/s11307-012-0564-0.

48.

Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.

White RL Jr, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbook BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, Shyr Y, Berry L, Zhao Z, Soong SJ, Leong SP; Sentinel Lymph Node Working Group.

Ann Surg Oncol. 2011 Dec;18(13):3593-600. doi: 10.1245/s10434-011-1826-9. Epub 2011 Jun 7.

49.

Amphiregulin exosomes increase cancer cell invasion.

Higginbotham JN, Demory Beckler M, Gephart JD, Franklin JL, Bogatcheva G, Kremers GJ, Piston DW, Ayers GD, McConnell RE, Tyska MJ, Coffey RJ.

Curr Biol. 2011 May 10;21(9):779-86. doi: 10.1016/j.cub.2011.03.043. Epub 2011 Apr 21.

50.

Distinguishing Ménétrier's disease from its mimics.

Rich A, Toro TZ, Tanksley J, Fiske WH, Lind CD, Ayers GD, Piessevaux H, Washington MK, Coffey RJ.

Gut. 2010 Dec;59(12):1617-24. doi: 10.1136/gut.2010.220061. Epub 2010 Oct 6.

Supplemental Content

Loading ...
Support Center